| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
2 companies
Julie Jordan is Chief Medical Officer at NGNE, with reported holdings spanning 2 companies. Julie Jordan's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $398K at current prices.
Our model assigns Julie Jordan a below-average insider score of 28/100, based on 3 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -56.2%.
Julie Jordan's largest disclosed position is in NGNE as Chief Medical Officer, worth about $333K. The NGNE filings lean toward selling, a net 828 shares.
Julie Jordan has 5 Form 4 filings on record from August 2023 to March 2026, across 2 companies: Chief Medical Officer at Neurogene (NGNE), 2024–2026; Chief Medical Officer at QTTB, 2023.
The 12 reported transactions were 5 open-market sales, 4 option exercises, 2 option or other derivative awards and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $21K.
The largest open-market sale was 828 shares of NGNE at an average $21.89 on March 26, 2026, about $18K.
All 3 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.